 
 Protocol with Statistical Analysis Plan Cover Page:   
 
Official Title:  Genomics, Environme ntal Factors and Social D eterminants of Cardiov ascular 
Disease in African -Americans Study (GENE-FORECAST): Sodium Intervention 
Trial ( SIT)/GENE -FORECAST SIT  
NCT number:   [STUDY_ID_REMOVED]  
Document Type:   Protocol with Statistical Analysis Plan (SAP)  
Document Date:  29JUL2 [ADDRESS_1040033] SIT  
29JUL 2024 
 
1 
  
Abbreviated Title:  GENE -FORECAST SIT  
NIH IRB #:  000070   
Version Date:  29JUL2024  
Title: Genomics, Environme ntal Factors and Social D eterminants of Cardiov ascular Disease in 
African -Americans Study (GENE -FORECA ST): Sodium Intervention Trial ( SIT)/GENE -
FORECAST SIT  
 
NIH Principal Investigator:  [INVESTIGATOR_759499], MD, PhD, MBA  (E) 
Office of the Clinical Director  
National Heart, Lung, and Blood Institute  
Building 10 -CRC, Rm 6-3142  
9000 Rockville Pi[INVESTIGATOR_111977], MD [ZIP_CODE]  
Phone: [PHONE_15858]  
E-mail: [EMAIL_14513]  
 
Investigational Agents:  
Drug Name:  [CONTACT_759584]:  Not applicable  
Sponsor:  Not applicable  
Manufacturer:  Pi[INVESTIGATOR_759500] -FORECAST SIT  
29JUL 2024 
 
2 
 TABLE OF CONTENTS  
TABLE OF CONTENTS  ................................ ................................ ................................ ................  2 
STATEMENT OF COMPLIANCE  ................................ ................................ ................................  6 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ...... 7 
1.1 Synopsis  ................................ ................................ ................................ ...........................  7 
1.2 Schema  ................................ ................................ ................................ .............................  8 
1.3 Schedule of Activities (SOA)  ................................ ................................ ...........................  8 
2 INTRODUCTION  ................................ ................................ ................................ ................  10 
2.1 Study Rationale  ................................ ................................ ................................ ..............  10 
2.2 Background  ................................ ................................ ................................ ....................  10 
2.3 Risk/Benefit Assessment  ................................ ................................ ................................  11 
2.3.1  Known Potential Risks  ................................ ................................ ............................  11 
2.3.2  Known Potential Benefits  ................................ ................................ .......................  12 
2.3.3  Assessment of Potential Risks and Benefits  ................................ ...........................  12 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ......................  13 
4 STUDY DESIGN ................................ ................................ ................................ ..................  14 
4.1 Overall Design  ................................ ................................ ................................ ................  14 
4.2 Scientific Rationale for Study Design  ................................ ................................ ............  15 
4.3 Justification for Dose  ................................ ................................ ................................ ..... 16 
5 STUDY POPULATION  ................................ ................................ ................................ ....... 16 
5.1 Inclusion Criteria  ................................ ................................ ................................ ............  16 
5.2 Exclusion Criteria  ................................ ................................ ................................ ...........  16 
5.3 Inclusion of Vulnerable Participants  ................................ ................................ ..............  17 
5.4 Lifestyle Considerations  ................................ ................................ ................................ . 17 
5.5 Screen Failures  ................................ ................................ ................................ ...............  17 
5.6 Strategies for Recruitment and Retention  ................................ ................................ ...... 17 
5.6.1  Costs  ................................ ................................ ................................ ........................  18 
5.6.2  Compensation  ................................ ................................ ................................ .........  18 
6 STUDY INTERVENTION  ................................ ................................ ................................ ... 18 
6.1 Study Interventions(s) Administration  ................................ ................................ ...........  18 
6.1.1  Study Intervention Description  ................................ ................................ ...............  18 
6.1.2  Dosing and Administration  ................................ ................................ .....................  18 
6.2 Preparation/Handling/Storage/Accountability  ................................ ...............................  [ADDRESS_1040034] Storage and Stability ................................ ................................ ..................  19 
6.2.4  Preparation  ................................ ................................ ................................ ..............  19 
6.3 Measures to Minimize Bias: Randomization and Blinding  ................................ ...........  19 
6.4 Study Intervention Compliance  ................................ ................................ ......................  19 
6.5 Concomitant Therapy  ................................ ................................ ................................ ..... 19 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ................................ ................................ .....................  20 
7.1 Discontinuation of Study Intervention  ................................ ................................ ...........  20 
7.2 Participant Discontinuation/Withdrawal from the Study  ................................ ...............  [ADDRESS_1040035] SIT  
29JUL 2024 
 
3 
 8.1 Screening Procedures  ................................ ................................ ................................ ..... 21 
8.2 Efficacy Assessments  ................................ ................................ ................................ ..... 21 
8.2.1  Clinical Evaluations  ................................ ................................ ................................  23 
8.2.2  Biospecimen Evaluations  ................................ ................................ ........................  23 
8.2.3  Correlative Studies for Research/Pharmacokinetic Studies  ................................ .... 27 
8.2.4  Samples for Genetic/Genomic Analysis  ................................ ................................ . 27 
8.3 Safety and Other Assessments  ................................ ................................ .......................  28 
8.4 Adverse Events and Serious Adverse Events  ................................ ................................ . 32 
8.4.1  Definition of Adverse Event  ................................ ................................ ...................  32 
8.4.2  Definition of Serious Adverse Events (SAE)  ................................ .........................  [ADDRESS_1040036] ................................ ................................ ........................  35 
8.4.8  Reporting of Pregnancy  ................................ ................................ ..........................  35 
8.5 Unanticipated Problems  ................................ ................................ ................................ . 35 
8.5.1  Definition of Unanticipated Problems (UP)  ................................ ...........................  35 
8.5.2  Unanticipated Problem Reporting  ................................ ................................ ...........  36 
8.5.3  NIH Intramural IRB Reporting of IND Safety Reports  ................................ ..........  36 
9 STATISTICAL CONSIDERATIONS ................................ ................................ ..................  36 
9.1 Statistical Hypothesis  ................................ ................................ ................................ ..... 36 
9.2 Sample Size Determination  ................................ ................................ ............................  36 
9.3 Populations for Analyses  ................................ ................................ ................................  38 
9.3.1  Evaluable for toxicity  ................................ ................................ ..............................  38 
9.3.2  Evaluable for objective response  ................................ ................................ ............  38 
9.3.3  Evaluable Non -Target Disease Response  ................................ ...............................  38 
9.4 Statistical Analyses  ................................ ................................ ................................ ........  38 
9.4.1  General Approach  ................................ ................................ ................................ ... 38 
9.4.2  Analysis of the Primary Endpoints  ................................ ................................ .........  38 
9.4.3  Analysis of the Secondary Endpoint(s)  ................................ ................................ ... 40 
9.4.4  Safety Analyses  ................................ ................................ ................................ ....... 41 
9.4.5  Baseline Descriptive Statistics  ................................ ................................ ................  41 
9.4.6  Planned Interim Analyses  ................................ ................................ .......................  41 
9.4.7  Sub-Group Analyses  ................................ ................................ ...............................  41 
9.4.8  Tabulation of individual Participant Data  ................................ ...............................  41 
9.4.9  Exploratory Analyses  ................................ ................................ ..............................  41 
10 REGULATORY AND OPERATIONAL CONSIDERATIONS  ................................ .........  41 
10.1  Informed Consent Process  ................................ ................................ ..........................  41 
10.1.1  Consent/Assent Procedures and Documentation  ................................ ....................  41 
10.1.2  Consent for minors when they reach the age of majority  ................................ ....... 41 
10.1.3  Telephone consent  ................................ ...................  Error! Bookmark not defined.  
10.1.4  Telephone assent  ................................ ................................ ................................ ..... 42 
10.1.5  Participation of Subjects who are/become Decisionally Impaired  .........................  [ADDRESS_1040037] SIT  
29JUL 2024 
 
6 
 STATEMENT OF COMPLIANCE  
The trial will be carried out in accordance with International Conference on Harmonisation Good 
Clinical Practice ( ICH GCP) and the following :  
• [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 
CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312 , and/or 21 CFR Part 8 12)  
National Institutes of Health ( NIH)-funded investigators and clinical trial site staff who are 
responsible  for the conduct, management, or  oversight of NIH -funded clinical trials have 
completed Human Subjects Protection and ICH GCP Training.  
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the Institutional Review Board ( IRB) for review and approval.  Approval of both 
the protocol and the consent form must be obtained before any participant is enrolled.  Any 
amendment to the protocol will require review and approval by [CONTACT_52590].  In addition, a ll changes to the consent form will be IRB -approved; a 
determination will be made regarding whether  a new consent needs to be obtained from 
participants who provided consent, using a previously approved consent form . 
  
GENE -FORECAST SIT  
29JUL 2024 
 
7 
 1 PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Title:  Genomics, Environme ntal Factors and Social D eterminants of 
Cardiov ascular Disease in African Americans Study (GENE -
FORECA ST): Sodium Intervention Trial ( SIT)/GENE -
FORECAST SIT   
Study Description : The objective of this study is to implement a sodium intervention 
investigation to assess the effect of increased dietary sodium intake on  
changes in blood pressure, vascular function, microbiome, whole 
blood epi[INVESTIGATOR_307999], whole blood and urine transcriptome  as outcome 
measures.  The study design will include a double -blind, cross -over 
treatment/placebo trial among [ADDRESS_1040038] blood pressure, whole blood epi[INVESTIGATOR_307999], whole blood and 
urine transcriptome, vascular function, microbiome and  blood 
pressure.   
Objectives:  
 Primary Objective:  
Define the effect of increased dietary sodium intake on microbiome 
and vascular function.  
Secondary Objective:  
1) Determine if increased sodium affects blood pressure.  
2) Determine if increased sodium affects whole blood epi[INVESTIGATOR_307999].  
3) Determine if increased sodium affects whole blood and urine 
transcriptome.  
  
  
Endpoint s: Primary:  
Vascular function  
Microbiome  
Secon dary:  
Blood pressure  
Whole blood epi[INVESTIGATOR_759501]:  Study population will include [ADDRESS_1040039] protocol.   
Phase:  <0. 
Description of 
Sites /Facilities  
Enrolling Participants : All protocol activities will take place at the NIH Clinical Center.  
 
Description of Study  
Intervention : Participants will be enrolled in a double -blind cross -over sodium 
chloride /placebo intervention trial.   Intervention product will be taken 
in capsule form (1 gram per capsule) [ADDRESS_1040040] SIT  
29JUL 2024 
 
8 
 Study Duration:  Participants will be enrolled concurrently along with ongoing GENE -
FORECAST protocol.  It is anticipated that it will take 36 months 
from enrollment to completion of data analyses.  
 
Participa nt Duration:  It will take 7 weeks for each participant to complete 4 visits to the 
Clinical Center during the trial.  
 
  
 
1.2 SCHEMA  
 
 
 
Figure 1: Randomized double -blind crossover treatment/control flowchart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participants will be randomized to a placebo or salt treatment  arm for two weeks (Period 1), 
followed by a wash -out period for three -weeks, ending with a cross -over to the alternative 
treatment arm for two weeks (Period 2).  The total length of participation is 7 weeks (Figure 1). 
Participants will be randomly assign ed by a computer -generated code.  
 
1.3  SCHEDULE OF ACTIVITIES (SOA)  
It is estimated that participants will spend approximately [ADDRESS_1040041], will take about 1.30 ho urs. 
 
Table 1: Estimated length of time for study procedures  
GENE -FORECAST  
recall Participants  
Sodium  
Placebo  
Washout 
period  
(3-week ) 
Placebo  
Sodium  
Randomization  
Period 1  
 Period 2  
t0 
Baseline  
        t1 
(week2)  
     t3 
(week7) 
        t1 
(week5)  
GENE -FORECAST SIT  
29JUL 2024 
 
9 
  NIH Clinic Visit  Estimated 
time 4 hours  Total 
Participants  Duration of 
Study  
a) Informed consent 
(baseline only)   20-30 
minutes  40 7 wks  
b) Baseline 
Questionnaires   1.75 hours  40 Baseline  
 
c) Phlebotomy  30 minutes  40 7 wks  
d) Physical 
examination  20 minutes  40 7 wks  
e) 24 diet recall  30 minutes  40 7wks  
f) Microbiome  15 minutes  40 7 wks  
g) Psychophysical 
Taste Task: Sucrose 
and Salt Detection 
Thresholds  30 minutes  40 7 wks  
h Psychophysical 
Taste Task: Sucrose 
and Salt Preference  20 minutes  40 7 wks  
i) Vascular Function  1.0 hrs.  40 7 wks  
    
 
Visit to the NIH Clinical Center:  
Once potential participant arrives at the Clinical Center, they will report to admissions and be  
greeted by [CONTACT_759536] -FORECAST -SIT staff who will escort him/her to a private room to  
administer informed consent and baseline questionnaires.  GENE -FORECAST -SIT staff 
(Research Nurse /Physician Assistant)  will subsequently escort potential participant t o 
phleboto my followed by [CONTACT_759537] -FORECAST -
SIT staff . A physical examination by [CONTACT_759538],  
they will then h ave a standar d physical exam, including blood pr essure measurement and vitals  
concluding with administration of vascular function tests using E ndo-PAT and SphygmoCo r by 
[CONTACT_759539].  Two blood pressure  measurements will  be obtain ed from the participant 
by [CONTACT_759540].  The blood pr essure will be 
measured usi ng a Dinamap and will  be obtain ed from the left arm after [ADDRESS_1040042] with the 
particip ant in a sitting position wi th legs uncrossed.  A 24 -hour diet recall will be administered 
by [CONTACT_3655] f rom the Clinical Center Nutrition Department .  Taste assessment will be administered 
by [CONTACT_759541] . 
 
Table 2: Specific activities by [CONTACT_759542] 1 
(baseline)  Visit 2  
(after 2 -
week 
treatment)  Visit 3  
(after 3 -
week 
washout)  Visit 4  
(after second 
2-week 
treatment)  
24-Hour nutrient recall  x x x x 
GENE -FORECAST SIT  
29JUL 2024 
 
10 
 Psychophysical Taste 
Task: Sucrose and Salt 
Detection Thresholds  x x x x 
Psychophysical Taste 
Task: Sucrose and Salt 
Preference  x x x x 
History and physical 
exam with medication 
history  x x x x 
Baeke’s physical activity 
questionnaire  x    
Pi[INVESTIGATOR_759502]  x    
Stool/skin/mouth swabs 
for microbiome analysis  x x x x 
Urine sample  x x x x 
Blood sample  x x x x 
Vascular function  x x x x 
24-hour blood pressure 
monitor given to 
participant  x  x  
24-hour blood pressure 
monitor returned by 
[CONTACT_3445]   x  x 
 
2 INTRODUCTION  
2.1 STUDY RATIONALE  
Little is known about the relationship between dietary sodium and gut microbiome ecosystem in 
humans; or how it might be altered by [CONTACT_759543]. The GENE -
FORECAST -SIT study will be the first to test the hypothesis that changes in dietary sodium 
intake are sufficient to influence the composition of the gut microbiome in association with 
sodium -induced changes in vascular function, epi[INVESTIGATOR_307999], transcriptome  and blood pressure in 
African Americans .   
 
2.[ADDRESS_1040043] SIT  
29JUL 2024 
 
11 
 It is well established that increased dietary sodium can predispose to an increase in blood 
pressure; particularly in ‘salt -sensitive’ individuals 3. In most individuals there are a powerful 
series of homeostatic systems (renal, neurohumoral, vascular) that function to maintain the 
normal set -point blood pressure across a very broad range of dietary sodium intakes. Yet, a sub -
set of ‘salt -sensitive’ i ndividuals exhibit changes in vascular function and modest elevations in 
blood pressure in response to relatively modest changes in dietary sodium intake 4.  It is 
noteworthy that several studies have suggested an apparent increased prevalence of ‘salt -
sensitive’ blood pressure among African  Americans 5.   
Commonly used animal models of hypertension often employ high dietary sodium intake as a 
means of inducing sustained hypertension. The Dahl Salt -Sensitive Rat is a genetic model of 
hypertension that becomes hypertensive upon the administration of a high -sodium diet; whereas 
the genetically related Dahl Salt -Resistant Rat remains normotensive despi[INVESTIGATOR_759503]. Although there are multiple factors that appear to mediate this genetic 
predisposition to salt -sensitive hypertension, an intrig uing recent report has noted a striking 
difference between the gut microbiome in Dahl salt -sensitive vs salt -resistant animals 6. In 
addition, recent studies have demonstrated a relationship between increased dietary sodium 
intake and modulation of the immune system in animal models 7,8. The proposed project seeks to 
further extend the working hypothesis that the effect of dietary sodium on vascular function and 
blood pressure may be modulated by [CONTACT_759544].  The selected dosage of sodium chloride is based on prior research.8-[ADDRESS_1040044] are shaped by [CONTACT_759545]. Conversely, the microbe 
composition of each individual’s gut can influence the digestion and generation of certain 
metabolites from certain foods.  The various patterns of gut microbiome composition have been 
implicated in the regulation of the immune system as well as the pathogenesis of obesity, 
autoimmune disorders and cardiovascular disease 11-13. For example, Stan Hazen’s team has 
shown striking differences in the human microbiome between vegetarians and those who are 
frequent  ‘meat -eaters’. This dietary difference is associated with differential generation of a 
microbe metabolite, trimethylamine -oxidase (TMAO).  Increased generation of the microbe 
metabolite, TMAO, is associated with increased risk of cardiovascular disease.  Moreover, it has 
been shown that pharmacologic inhibition of the generation of this gut microbe metabolite 
attenuates athe rogenesis in animal models. Taken together, these clinical and animal model 
studies suggest a causal link between dietary patterns, the gut microbiome and cardiovascular 
disease.  
 
2.3 RISK/BENEFIT ASSESSMENT  
2.3.[ADDRESS_1040045], indigestion, nausea, 
vomiting, headaches, mild elevations in blood pressure, mild changes in blood chemicals 
(elect rolytes), lightheadedness, tiredness, mild s welling of arms/legs, and/or diarrhea.  Although 
it would be very rare to have an allergic reaction to the capsules, any time a new medication is 
GENE -FORECAST SIT  
29JUL [ADDRESS_1040046] a disproportionately higher 
prevalence of cardiovascular disease  
2.3.3 Assessment of Potential Risks and Benefits  
The  risks are very minor and include:  
 
Vascular function testing and 24 -hour blood pressure monitor: Subject  may experience brief 
discomfort, pain or tingling sensations  when  the blood  pressure  cuff is inflated  to reduce  
blood  flow to the hand  for a few minutes  during  the vascular function  tests and/or  24-hour 
blood  pressure  monitor.  
 
Phlebotomy:  Transient  discomfort  and minor  bruising  may occur  when  blood  is drawn.  
 
Microbiome  collection: :  Collection will comprise of skin, saliva and stool samples utilizaing 
Norgen kits.  These tests carry very minor risks, with the transient mild skin irration  at the sites 
where your skin is swabbed although this is very unlikely.  
 
Salt capsules:  Sodium  chloride  is approved  by [CONTACT_572642]  (FDA)  for a 
variety  of clinical  uses and is available over the counter (OTC) . The  capsules  given  as part of 
this study  contain  sodium  chloride  (salt)  in powder  form  or placebo. The amount of salt add ed 
to subject’s  usual daily diet as part of this study is equivalent to about half a teaspoon  of salt 
or a packet  of Ramen  chicken  noodle  soup.  The salt capsules  are generally  safe and well 
tolerated but side effects can occur including discomfort while swallowing, increased thirst, 
indigestion, nausea, vomiting, headaches, mild elevations in blood pressure, mild changes in 
blood chemicals (electrolytes), lightheadedness, tiredness,  mild swelling  of arms/legs,  and/or  
diarrhea.  Although  it would  be very rare to have  an allergic  reaction  to the capsules in this 
study, any time a new medication is taken there is a small chance (less than 1 person out of 
1000 treated) that you could have an allergic reaction which would most commonly manifest 
itself as a rash.  
The GENE -FORECAST -SIT staff will monitor  subjects during  study  participation  to detect  any 
potential  serious  adverse reactions to the salt  capsules.  
 
24 Hour food intake recall : Subjects may be  asked a series of questions by [CONTACT_759546] [ADDRESS_1040047] SIT  
29JUL 2024 
 
13 
  
Mouth: At each clinical center visit, saliva samples from subjects  mouth will be collected by 
[CONTACT_759547] a sterile collection tube . Providing study samples of these specimens 
that the body normally excretes will not cause any additional pain or discomfort.  
 
Stool:  Subjects  will be provided with a stool specimen collection kit prior to their visit. There 
may be some physical discomfort of inability to obtain sample (e.g ., constipation) . Providing 
study samples of these specimens that the body normally excretes will not cause any additional 
pain or discomfort.  
 
Urine: Subjects will be asked to give a urine sample in a sterile cup provided  at the NIH Clinical 
Center  to test for urine chemistries (e.g. , potassium, chloride, sodium). There may be  physical 
limitations in inability to provide sample (e.g. dehydration).  Providing study samples of these 
specimens that the body normally excretes will not cause any additional pain or discomfort.  
 
 Psychophysical Taste Task with sucrose and salt detection thresholds  and preference : Sucrose 
and salt detection thresholds  and preference  will be assessed to get  subject responses to 
sweetness or saltiness. There may be a discomfort of tasting solutions and repeated spi[INVESTIGATOR_759504].  
 
Physical activity and sleep questionnaire: Subjects  will be asked  a series  of questions  related  
to their physical  activity  and sleep.  They may experience minor psychological discomfort of 
answering personal questions regarding their physical activity and sleepi[INVESTIGATOR_285816].  
 
 
GENE -FORECAST-SIT staff will closely monitor the study participant in order to  detect any 
potential severe adverse reactions to study medication. Specifically, GENE -FORECAST -SIT staff 
will contact [CONTACT_759548] +/ -[ADDRESS_1040048] on vascular 
function and microbiome?  Vascular function  
Microbiome  
 A sub-set of ‘salt -sensitive’ 
individuals exhibit changes 
in vascular function and 
modest elevations in blood 
pressure in response to 
relatively modest changes in 
GENE -FORECAST SIT  
29JUL [ADDRESS_1040049] suggested an 
apparent increased 
prevalence of ‘salt -sensitive’ 
blood pressure among 
African Americans  
The various patterns of gut 
microbiome composition 
have been implicated in the 
regulation of the immune 
system as well as the 
pathogenesis of obesity, 
autoimmune disorders and 
cardiovascular disease . 
Secondary    
What effect does increase dietary 
sodium have on blood pressure?  
 
What effect does increase dietary 
sodium have on whole blood 
epi[INVESTIGATOR_307999]?  
 
 
What effect does increase dietary 
sodium have on whole blood and urine 
transcriptome  
 Blood pressure  
 
DNA methylation  
 
RNAseq  
 
 It is well established that 
increased dietary sodium 
can predispose to an 
increase in blood pressure . 
DNA methylation is a well-
established measure of the 
epi[INVESTIGATOR_307999].  
RNAseq is a well -
established measure of 
genetic transcriptome.  
 
[ADDRESS_1040050] protocol.  Those in the upper tertile of vascular stiffness (as assessed by [CONTACT_759549]) will be oversampled.  Participants will be rand omized to a placebo or salt 
treatment  arm for two weeks (Period 1), followed by a wash -out period for three -weeks, ending 
with a cross -over to the alternative treatment arm for two weeks (Period 2).  The total length of 
participation is 7 weeks (Figure 1).   
 
Study Site:  
All study activities will take place at the NIH Clinical Center. The NIH Clinical Center  Pharmacy 
will dispense the treatment and placebo capsules.  
 
Statement of hypotheses:  
* Based on population history, it is postulated that the genomic architecture of individuals of 
African ancestry has been shaped by [CONTACT_759550] -poor conditions that may predispose to an increased 
sensitivity and avidity for sodium retention in African Americans.  
GENE -FORECAST SIT  
29JUL 2024 
 
15 
 * Increased dietary sodium intake is associated with vascular dysfunction and increased blood 
pressure in certain sub -sets of normotensive African Americans; and this effect is augmented in 
individuals with baseline evidence of vascular dysfunction.  
* Increased dietary sodium intake is associated with changes in the whole blood epi[INVESTIGATOR_759505].  
* Increased dietary sodium intake is associated with changes in the whole blood and urine 
transcriptome as assessed by [CONTACT_16638] -seq. 
* Increased dietary sodium intake is associated with changes in the skin, oral and gut microbiome.  
* Increased dietary sodium take is associated with whole blood epi[INVESTIGATOR_307999]/transcriptome 
molecular signature [CONTACT_759585] a chronic “pro -inflammatory state.”  
 
Type/design of trial:  
A randomized, double -blind, placebo -controlled, cross -over design will be implemented.  
 
Method to minimize bias:  
Participants will be randomly assigned by a computer -generated code.  
 
Number of study arms and intervention duration:  
Participants will be randomized to a placebo or salt treatment  arm for two weeks (Period 1), 
followed by a wash -out period for three -weeks, ending with a cross -over to the alternative 
treatment arm for two weeks (Period 2).  The total length of participation is 7 weeks (Figure 1).  
 
Name [CONTACT_64499]:  
Sodium Chloride  
 
4.[ADDRESS_1040051] increase in dietary sodium intake is sufficient to 
change the gut microbiome and trigger alterations in the blood transcriptome that may mediate 
the resultant in the well described salt -sensitive changes in  vascular function , epi[INVESTIGATOR_307999], 
transcriptome and blood pressure observed in African Americans . The study design as a 
randomized, double -blind, placebo -control cross -over design enables each participant to serve as 
her/his own control in response to the die tary salt intervention. The cross -over design allows for 
an intervening ‘wash -out’ period to ensure that the participant’s diet and sodium homeostasis 
returns to baseline. The design’s use of each participant as her/his own control reduces the 
impact of in ter-individual variability in the basal dietary habits and microbiome; and optimizes 
statistical power to detect differences in baseline blood transcriptome gene expression profiles 
and gut microbiome in response to the dietary intervention.  Our previous studies of the human 
transcriptome indicate that the current design is very robust to detect changes in gene expression 
by [CONTACT_387282], RNA -seq and vascular function. The randomization ensures that the 
sequence order of the intervention (placebo vs salt tablets) is due to chance and avoids a 
systematic ‘contamination’ or carryover effect of the active treatment. The double -blind 
administra tion of tasteless capsules ensures that neither the participant or research staff are aware 
that there could be an i ncreased ingestion of dietary salt. The dose of sodium chloride in the 
capsule has previously been shown to affect biomarkers sensitive to salt balance such as 
measures of the renin -angiotensin -aldosterone system and blood pressure. The daily dose of 
sodiu m chloride tablets given in the protocol falls well within the wide variance of ‘normal’, 
GENE -FORECAST SIT  
29JUL 2024 
 
16 
 safe, intake in various cultures around the world. The increment in salt intake beyond the 
participant’s usual diet is equivalent to eating [ADDRESS_1040052] used source of oral samples is saliva (collected by 
[CONTACT_759551]).  The collection of the skin microbiome samples is commonly performed 
using the swabbing method  28.  The sampling for skin microbiome was guided by [CONTACT_759552] 29: Sebaceous and moist 
microenvironments. For the first, the Retroarticular Crease was chosen and for the latter, the 
Antecubital Fossa was selected. These sites provide also the advantage of being relatively less 
exposed than dry sites such as the forearm and hence less likely to have the external environment 
microbiome over -represented.  
The oral samples are not collected to investigate gut microbiome but rather to evaluate changes 
in oral microbiome [ADDRESS_1040053] and then patterns of changes between sites are 
considered.  
 
4.3 JUSTIFICATION FOR DOSE 
Sodium chloride (1gm/capsule)  and placebo will be dispensed by [CONTACT_4494]. Participant 
would be instructed to take [ADDRESS_1040054] the outcome parameters and doesn’t pose any health dangers.  This dosage is 
the standard amount used i n such protocol.8-[ADDRESS_1040055] participants between 21 
and 65 years of age.  I This criterion is inclus ive of self-identified  AA of both Hisp anic, Latino  
and non-Hispanic, Latino  ethnicities. Normotensive participants with systolic blood pressure 
(SBP) <140 mm Hg and diastolic blood pressure (DBP) < 90 mm Hg and the absence of a history 
of prior diagnosis of hypertension.  
• Willingness and ability to participate in study procedures.  
 
5.2 EXCLUSION CRITERIA  
• Individuals who are pregnant or breast -feeding.  
• Individuals with high blood pressure or a history of hypertension.  
• Individuals with a history of myocardial infarction, stroke, heart failure, diabetes, chronic  
liver or kidney diseases.  
• Individuals who are taking antihypertensive , antidepressants, antidiabetic  and antibiotic  
medications.  
• Individuals currently participating in another NIH protocol.  
• Individuals unable to provide informed consent.  
GENE -FORECAST SIT  
29JUL 2024 
 
17 
  
5.3 INCLUSION OF VULNERABLE PARTICIPANTS  
The study will not involve vulnerable groups other than NIH employees who volunteer for 
participation in study. NIH employees will be provided requisite information according to 
OHSRP Policy 404  prior to agreeing to participate in study.  
 
5.4 LIFESTYLE CONSIDERATIONS  
During the study, participants are asked to:  
• Reframe from taking antibiotics. Taking such mediation will result in early withdrawal.  
 
5.[ADDRESS_1040056] prior to randomization will be considered a screen failur e and not 
enrolled in the study.   Participants who consent to participate but present with  systolic blood 
pressure (SBP) > 140 mm Hg and di astolic blood pressure (DB P) >90 mm Hg at physical 
examination will also be considered a screen failure.  
 
Screen failures are defined as participants who consent to participate in the study but are not 
subsequently assigned to the study intervention or enter the study.  A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants  to mee t the 
Consolidated Standards of Reporting Trials (CONSORT) , publishing requirements and respond to 
queries from regulatory authorities.  Minimum information will include demography, screen 
failure details, eligibility crit eria, and any serious adverse event (SAE) . 
 
5.6 STRATEGIES FOR RECRUITMENT AND RETENTION  
• Target study sample:  
Participants will be recruited from those who previously participated in the GENE -FORECAST 
protocol. A total of 40 normotensive African American men and 21 -65 years old will comprise 
the total sample size. We anticipate screening 150 potential participants . 
 
• Anticipated accrual rate:  
40 
 
• Source of participants:  
Former GENE -FORECAST participants.  
 
• Recruitment venues:  
The  GENE -FORECAST -SIT staff  will contact [CONTACT_759553] -FORECAST -SIT protocol and screen for eligibility over the telephone based on self -
report information.  
 
• How potential participants will be identified:  
A listing of former normotensive GENE -FORECAST participants will be generated, including 
those in the upper tertile with vascular stiffness, by [CONTACT_759554] -
contact [CONTACT_759555] -FORECAST protocol.   
GENE -FORECAST SIT  
29JUL 2024 
 
18 
 •  
5.6.[ADDRESS_1040057] to participants.  
 
5.6.2 Compensation  
Participants will receive $50 per visit disbursed through the Research Volunteer System (RVS) 
for Visits 1,2, 3, and 4.  A final payment  for $[ADDRESS_1040058] deposit to the 
participant by [CONTACT_759556] (24hr 
BP monitor; Smart -Bottles).  The total possible compensation for participating in the completed 
study will be $500.  Participant will also  receive a $[ADDRESS_1040059] pre -paid tax i trip to the NIH Clinical Center.  
 
6 STUDY I NTERVENTION  
6.1 STUDY INTERVENTIONS (S) ADMINISTRATION  
6.1.1 Study Intervention Description  
There are no unapproved drugs or devices being used in this study.  
Sodium Chloride  is Food and Drug Administration (FDA) approved for a variety of clinical 
conditions and is included in a wide variety of commonly consumed processed foods.  
 
6.1.2 Dosing and Administration  
Sodium Chloride and Placebo : Sodium Chloride (1gm/capsule)  and corresponding placebo will 
be provided by [CONTACT_4494]. Participant will be instructed to take [ADDRESS_1040060] the outcome parameters and 
doesn’t pose any health dangers.  This dosage is the standard amount used in such protocol.8-10 
 
[IP_ADDRESS]  Dose Escalation  
There will be no dose escalation.  Participants will be instructed to take 3 assigned salt or 
placebo pi[INVESTIGATOR_759506] a total of 3 grams.  
 
[IP_ADDRESS]  Dose Limiting Toxicity  
Not applicable  
 
[IP_ADDRESS]  Dose Modifications  
Not applicable  
 
[IP_ADDRESS]  Drug Administration  
Participant will be instructed to take 3 pi[INVESTIGATOR_759506] a total of 3 grams.  If one capsule is 
missed per day, participant should not make up t he next day by [CONTACT_759557] . 
 
6.2 PREPARATION /HANDLING /STORAGE /ACCOUNTABILITY   
6.2.1 Acquisition and Accountability  
The sodium chloride and placebo capsules will be manufacture d by [CONTACT_25715][INVESTIGATOR_759507], [LOCATION_001] and sent directly to the NIH Clinical Center Investigational Drug & 
Research Section Outsourcing Unit (IDOU).  The sodium chloride and placebo capsules will be 
subsequently sent to the NIH Clinical Center pharmacy who will be dispense directly to 
GENE -FORECAST SIT  
29JUL [ADDRESS_1040061] will be discarded by [CONTACT_759558].  
 
6.2.2 Formulation, Appearance, Packaging, and Labeling  
The sodium chloride and placebo capsules will be formulated by [CONTACT_25715][INVESTIGATOR_759507], [LOCATION_001] based on FDA guidelines. There will be no distinguishing characteristics 
between both capsules. The sodium chloride and placebo capsules will be put in a separate 
‘smart bottle’ by [CONTACT_759559] -blind 
participant ID list previously provided by [CONTACT_976] [INVESTIGATOR_759508] t wo times a day. The smart 
bottle technology will electronically monitor adherence  to daily treatment and is designed to 
remind participant to take treatment and to alert when treatment has been missed.  Smart bottles 
will be purchased from a reputable vender with a history of collaboration in such trials.  
 
6.2.[ADDRESS_1040062] from 
such elements.  
 
6.2.4 Preparation  
The Clinical Center pharmacy will dispense the sodium chloride and placebo capsules in 
separate smart bottles. Capsules do not involve thawing, diluting, mixing and 
reconstitution/preparation.  
 
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING  
A randomized, double -blind, placebo -controlled, cross -over design will be implemented (Figure 
1).  Participants will be randomly assigned by a computer -generated code based on study ID.  All 
study staff will be blinded to randomization throughout the trial  period.  The randomized list will 
be provided to the Clinical Center pharmacy who will have the key to specific participant 
randomization.  
 
6.[ADDRESS_1040063] for 
sodium/potassium at baseline and at the end of each treatment test as an additional measure of 
adherence to the dietary sodium intervention.  
 
6.5 CONCOMITANT THERAPY  
Antibiotics are excluded from this trial.  However, any other prescription medication is defined as 
a medication that can be prescribed by a properly authorized/licensed clinician is allowable.  
GENE -FORECAST SIT  
29JUL 2024 
 
20 
 Medications will be reported in the Case Report Form (CRF) as concomitant prescription 
medication, including over -the-counter medications and supplements.  
 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
7.1 DISCONTINUATION OF STUDY INTERVENTION  
Participant will be discontinued from participation in study if:  
• Completion of study trial  
• If any clinical adverse event (AE), laboratory abnormality, or other medical condition or 
situation occurs such that continued participation in the study would not be in the best 
interest of the participant  
• Positive pregnancy test  
• Participant unable to receive study intervention for two consecutive days.  
Any clinically relevant finding will be reported as an AE. All study related indices will be 
recorded and maintained up to the time of discontinuation.  Clinical staff will also follow -up with 
participant to capture AE, serious adverse events (SAE), and un anticipated problems (UPs)  
 
7.2 PARTICIPANT DISCONTINUATION /WITHDRAWAL FROM THE STUDY  
Participants are free to withdraw from participation in the study at any time upon request, or upon 
the development of an adverse reaction due to exposure to intervention.  
 
PI [INVESTIGATOR_759509]:  
• Significant study intervention non -compliance  
• If the participant meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation  
• Death  
• Screen failure  
 
The reason for participant discontinuation or withdrawal from the study will be recorded on the 
‘Current Status” CRF. Subjects who sign the informed consent form and are randomized and 
receive the study intervention and subsequently withdraw or are withdra wn or discontinued from 
the study will be replaced.  Prior to removal from study, efforts will be made to have participant 
complete a safety visit approximately one week following the last dose of study product.  
 
7.[ADDRESS_1040064] -SIT staff .  
The following actions will be taken if a participant fails to return to the clinic for a required study 
visit:  
• The GENE -FORECAST -SIT staff  will attempt to contact [CONTACT_759560]/or should 
continue in the study.  
GENE -FORECAST SIT  
29JUL 2024 
 
21 
 • Before a participant is deemed lost to follow -up, the GENE -FORECAST -SIT staff  will 
make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls 
and, if necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact [CONTACT_9145]’s 
medical record or study file.  
• Should the participant  continue to be unreachable, he or she will be considered to have 
withdrawn from the study with a primary rea son o f lost to follow -up. 
 
[ADDRESS_1040065] via the ‘Call Back’ protocol.  The Research Nurse  will contact [CONTACT_759561] -FORECAST -SIT and screen via the telephone for eligibility 
based on self -reported health information.  Participant who agree to participate in study will be 
scheduled for baseline clini cal visit based on availability  and subsequently screened again at the 
Clinical Center. All participants will undergo screening activities upon coming to the NIH. 
Female participants will undergo a pregnancy test after consent signature.  Participants who 
consent to participate in the trial and subsequently have a positive pregnancy test prior to 
randomization will be considered a screen failure and not enrolled in the study.    
 
8.2 EFFICACY ASSESSMENTS  
1.  Salt/Placebo Intervention: Capsules will be dispensed by [CONTACT_759562].  
2.  Flow Activating Cell Sorting ( FACS ) Analysis: Characterization of Leukocytes 
Populations :   As part of assessing the whole blood epi[INVESTIGATOR_759510] , the protocol 
will perform an in -depth characterization of  the heterogeneous mixture of leukocytes circulating 
in the blood and how this profile might be altered in response to the dietary sodium intervention.   
We will utilize the NHLBI’s Flow Cytometry Core in collaboration with [CONTACT_759587] McCoy. We 
will collect perip heral blood samples at the 4 time points (visit 1, 2 3 and 4). The FACS analysis 
will define changes in immune cell -type profi les as well as facilitate the isolation of DNA/RNA 
from specific immune cell sub -types (e.g. CD4 T -cells; CD8 T -cells, Monocytes etc.)  for 
epi[INVESTIGATOR_759511].   
3. Vascular function testing:  These tests will be done using specialized non -invasive 
machines, such as SphygmoCor and EndoPAT, to assess vascular health.  
4.  24-hour ambulatory blood pressure monitoring: Participants will be given an ambulatory 
blood pressure monitoring to device that will be worn for [ADDRESS_1040066] 24 hours using an automated dietary analysis software application developed 
by [CONTACT_759563]. The intakes for 108 nutrien ts (including salt) will be calculated for each participant 
based on individual diet.  
6.   Psychophysical Taste Task: Sucrose and Salt Detection Thresholds : Sucrose and  salt 
detection thresholds will be assessed using a two -alternative forced -choice staircase procedure 
GENE -FORECAST SIT  
29JUL 2024 
 
22 
 was developed at the Monell Center for Adults.14-16 The two -alternative forced choice is a 
psychophysical method developed to elicit responses about an individual’s experience regarding 
a stimulus. It focuses on the evaluation of a single attribute (e.g., sweetness or saltiness), and the 
stimulus is adjusted based on the individual’s responses .17-[ADDRESS_1040067] trial and each subsequent trial, subjects will be presente d with pairs of 
solutions in random order; within each pair, one solution will be distilled water, and the other 
will be the taste stimulus. Subjects will be instructed to taste the first solution presented within 
the pair, swish the solution in their mout h for 5 seconds, and expectorate. This will be repeated 
for the second solution within the pair. Between solutions, subjects will rinse their mouth with 
water; they will rinse once within a pair, and twice between successive pairs. After tasting both 
solut ions within a pair, subjects will be asked to point to the solution that has a non -neutral taste. 
A tracking grid will be used to record subjects’ response.19-21  This method eliminates the need 
for a verbal response and has been shown to be an effective method for assessing both taste and 
olfaction in children.19,22 The task takes approximately 30 minutes to complete.  
7.  Psychophysical Taste Task: Sucrose and Salt Preference: Sucrose and salt preference will 
be assessed using a two -series paired comparison -tracking method developed at the Monell 
Center for Adults.14-16 Subjects will be presented with pairs of solutions differing in sucrose 
concentration (3, 6, 12, 24, and 36 g per 100 mL) and salt (0.92 –6.14% wt/vol NaCl ). They will 
be asked to taste the solutions without swallowing and point to which of the pair they liked 
better. Subsequently, each pair presented will  be determined by [CONTACT_423]’s preceding 
preference choice. The entire task is then repeated with the stimulus pairs presented in reverse 
order. After completion of the taste task, the geometric mean of the sucrose concentrations 
chosen will be determined . This serves as  an estimate of the participant's most preferred level of 
sucrose.22-23 The task takes approximately 15 minutes to complete.  
8. Baecke’s Physical Activity Questionnaire:  Physical activity will be assessed using 16 
questions involving three habitual physical activities (occupational physical activity, physical 
exercise, and leisure activities) during the previous 12 months.24 
9. Pi[INVESTIGATOR_160976] (PSQI):   This is a 19 -item self -rated questionnaire for 
evaluating subjective sleep quality over the previous month.25 
10. Microbiome: Skin, saliva and stool samples will be collected by [CONTACT_759536] -FORECAST -
SIT staff  based on the utilization of Norgen kits.  Participant will be swabbed in three locations 
of the skin and will spit in a prepared value. Subjects will be required to not shower within [ADDRESS_1040068], an initiative to generate resources and facilitate the characterization of the human 
microbiota  (Human Microbiome Project, Nature, 2012 ). Stool kits will be previously mailed to 
participant for collection and participant will give stool sample to GENE -FORECAST -SIT staff 
at the clinic appointment . 
 
It is estimated that participants will spend approximately [ADDRESS_1040069].  All  procedures and details for each can 
be found in the study’s Manual of Operation (MOP).  
 
Table 1: Estimated length of time for study procedures  
 NIH Clinic Visit  Estimated 
time 4 hours  Total 
Participants  Duration of 
Study  
a) Informed consent 
(baseline only)   20-30 
minutes  40 7 wks  
b) Phlebotomy  30 minutes  40 7 wks  
 c)Physical 
examination  20 minutes  40 7 wks  
d) Baseline 
Questionnaires:   
Baecke’s Physical 
Activity  
Pi[INVESTIGATOR_759512]  1.45 hours  40 Baseline   
e) 24 diet recall  30 minutes  40  7wks  
f) Psychophysical 
Taste Task: Sucrose 
and Salt Detection 
Thresholds  30 minutes  40  7 wks  
g) Psychophysical 
Taste Task: Sucrose 
and Salt Preference  15 minutes  40 7 wks  
h) Microbiome  15 minutes  40 7 weeks  
i) Vascular Function  1.0 hrs  40 7 wks  
    
 
8.2.1 Clinical Evaluations  
Physical examination:  A physical examination will be performed by [CONTACT_759564]/medication history and measurements of height and weight. Vital signs 
including temperature, pulse, respi[INVESTIGATOR_1520], and blood pressure, will be also be collected.  
 
Radiographic or other imaging assessments:   
Radiology or other imaging will not be conducted  in this study.  
 
8.2.[ADDRESS_1040070] SIT  
29JUL 2024 
 
24 
 (CLIA).  Blood, urine and stool samples will be collected from the Clinical Center by [CONTACT_759565] -FORECAST -SIT staff . The samples are  brought to PI’s lab  by [CONTACT_759566].  Shipment of 
blood and microbiome samples for each visit per participant will be sent overnight for assay in 
dry ice in compliance with standard procedures. Each sample will be labelled with participant 
study ID.  
 
Urine sample: (small  quantity, 1 cup 90 m l) 
1. Urine chemistries (e.g. sodium , chloride, potassium )  
2. Urine creatinine and microalbumin (ACR)  
3. Urine protein to creatinine ratio (PCR)  
1. Osmolality  
2. Urea Nitrogen  
3. Urine exosomes (RNA/microRNA)  
 
 
Microbiome  samples : 
Stool/At home collection kit (quantity = 2 grams):  
Skin: swab of inner elbow and behind ears  
Oral: saliva  
 
Blood  samples: 
 
Fasting samples  for clinical chemistries: 
  
 
Blood  samples:  
  
          Clinical Center 
Research Lab 
Test 
Lab test  Volume 
Tube (ml)  Number of 
Tubes  Total 
Volume 
(ml) Total 
Volume 
(tablespoon)  Tube type  
CBC: CBC with 
differential count  
4 2 8 0.54 Lavender  HbA1C: A1C  
 
Homocysteine  
Fasting lipid 
panel (serum):  
3.5 2 7 0.47 green/yellow  Mineral panel  
Acute Care Panel  
GENE -FORECAST SIT  
29JUL 2024 
 
25 
  Total Protein  
ApoA1 and 
ApoB: APOAB  
Pro-BNP: BNP1  
C-reactive 
protein: CRPHS 
(high sensitivity 
CRP)  
Hepatic Panel  3.5 1 3.5 0.24 Gold  Serum hCG  
Serum Cortisol  
(CORT)  
8.[ADDRESS_1040071]  Serum 
Aldosterone   
(ALD03,ADS01, 
ADS02)  
Clinical Center 
Research Labs 
Total  19.[ADDRESS_1040072]  Volume 
Tube 
(ml) Number 
of 
Tubes  Total 
Volume 
(ml) Total 
Volume 
(tablespoon  Tube type  
 
4 1 4 0.27 Lavender/EDTA  DNA isolation 
(research, whole 
blood)  
RNA/miRNA 
isolation (whole 
blood)  2.5 2 5 0.34 PaxGene  
Plasma for research 
archiving  4 1 4 0.27 Green/ Lithium Heparin  
 
3.[ADDRESS_1040073]   
Research tube for 
specialized 
endothelial function 
markers (e.g. 
VCAM -1, VEGF)  
GENE -FORECAST SIT  
29JUL 2024 
 
26 
 Research tube for 
specialized 
inflammatory 
markers (e.g. IL6, 
TNF alpha)  
Plasma Renin 
Activity (PRA, 
PRAK1)  4 1 1 0.20 Lavendar/EDTA  
Serum for research 
archiving  3.[ADDRESS_1040074]  
FACS Analysis  10 4 40 2.71 Green/ Sodium Heparin  
Non-Clinical 
Center Research 
Labs Total  27.5 10 60 4.06   
Total per visit        
(4 visits)  47 16 87 5.88   
 
Microbiome:  
 
BODY SITE  SPECIMEN  COLLECTI ON TUBE  
 
Oral Cavity   
 
Saliva  
 
  
Saliva DNA  Collection, 
Preservation, and Isolation 
Kit  
 
 
Skin  Retroauricular Crease ( Left)  
Swab Collection and DNA 
System  Retroauricular Crease ( Right ) 
Antecubital Fossa ( Left) 
Antecubital Fossa (Right)  
 
GI Tract   
Stool   
Norgen  Stool Nucleic Acid 
Collection and Preservation 
System  
 
Total volu me of blood collected per visit = [ADDRESS_1040075] SIT  
29JUL 2024 
 
27 
 right retroarticular crease, as well as, the left and right antecubital fossa . Stool microbiome 
samples will be collected in a stool kit mailed to participants prior to clinic visit.  Detailed 
instructions for the preparation, handling, storage, and shipment of specimens will be explained 
in the study’s MOP . 
 
8.2.3 Correlative Studies for Research/Pharmacokinetic Studies  
The protocol will not include correlative studies for research/pharmacokinetic studies.  
 
8.2.4 Samples for Genetic /Genomic  Analysis  
[IP_ADDRESS]  Description of the scope of genetic/genomic analysis  
• Analyses will include whole blood epi[INVESTIGATOR_759513] .  
• Germline and/or somatic analysis will not be conducted.  
• Whole blood and urine will be the biospecimen s used for analyses. Privacy and 
confidentiality of medical information/biological specimens will be maximized . 
• No personal identifier will be maintained – including protected health information (PHI).  
Rather, participant will be assigned a unique numerical personal study identifier resulting 
in the unlikely occurrence of potential identification.  
• Clinical and demographic information will be collected on each participant.  Participant 
nor family members can be identified due to the use of a numerical personal study 
identifier.   
• All coded pa rticipant, demographic, survey, medical and biological information will  be 
stored in a medi cal file and a secured NIH d atabase with app ropriate IT security measures 
(e.g. de- identifi ed codes; encryption; password a ccess pro tection) to  maximize the 
protection of p rivacy. Only the database manager will have access to the password key 
for code.   
• Pedigree information will not be published.  
 
• The personal identifier will not be released to any third party.  
• No personal identifier containing data/sample information will be shared with other 
investigators.  Information will only be deposited into a relevant controlled access 
database as mandated by [CONTACT_377509].  
 
• For additional protection of confidentiality, all hard -copy information will be maintained 
in a locked file -cabinet with access only by [CONTACT_759567] -Base manager.  
Hard -copy information will be maintained and destroyed based on the duration 
mandated by [CONTACT_377509]. In addition, we will use a custom designed NIH database -
Clinical Trial Data Base (CTDB) d esigned for the collection and sto rage of study indices  
from study participants.  A ccess to stu dy particip ants’ info rmation is limited to  only a 
few of the investig ators and support st aff.  The database has passwo rd protection, 
stratified access, and firewall protection. 
 
GENE -FORECAST SIT  
29JUL 2024 
 
28 
 • Furthermore, to  help us protect  participant’s  privacy,  this study  has obtained  a 
Certificate  of Confidentiality  from  the National  Institutes  ofHealth.  Researchers  
cannot  release identifiable  information  to any federal,  state,  or local  civil,  criminal,  
administrative,  legislative,  or other  proceedings.  Researchers  will utilize  the 
Certificate  to minimize risks by [CONTACT_1583] a level of protection to study participants.  
 
• The Certificate  cannot  be used to resist  a demand  for information  from  personnel  of the 
United  States  Government  that is used for auditing  or evaluation  of federally  funded  
projects  or for information  that must  be disclosed  in order  to meet  the requirements  of 
the federal  Food  and Drug  Administration  (FDA).  
 
• The Certificate  of Confidentiality  does not prevent  any participant  or a member  of their 
family  from  voluntarily  releasing  information  about  a participant  involvement  in this 
research.  In the event that an  employer, insurer  or other  person  obtains  a participant’s  
written  consent  to obtain  research  information,  then the Certificate of Confidentiality 
cannot be used  to withhold  information.  
[IP_ADDRESS]  Management of Results  
Participants will be mailed a letter following baseline visit at the NIH Clinical Center (which is a 
CLIA certified lab) with results from their clinical visit, including Body Mass Index with health 
definitions, glucose, blood pressure.  
[IP_ADDRESS]  Genetic counseling  
Genetic counseling will not be provided.  We are not doing gene sequencing as a part of the 
study, therefore reporting the possibility of incidental findings is not applicable.  
 
[IP_ADDRESS] Safety and  Other Assessments  
Table 3: List and description for study procedures  
 NIH Clinic Visit  Description  
a) Physical 
examin ation  Height, weight, temperature, pulse, respi[INVESTIGATOR_1520], blood 
pressure conducted by [CONTACT_759568], 
Physician Assistant will perform physical examination.  
b) Phlebotomy  Standard clinical  laboratory chemistry - including whole 
blood for DNA methylation epi[INVESTIGATOR_759514]  
c) Urine  Urine sample for RNAseq  transcriptome collected by [CONTACT_759569]  
d) Microbiome  
     Skin, sal iva, stool  Swab, saliva and stool kits will be used to assess microbiome 
collected by [CONTACT_759570] -FORECAST -SIT staff  
e) Baseline 
Questionnaires   Pi[INVESTIGATOR_160976] (PSQI ):  This is a 19 -item 
self-rated questionnaire for evaluating subjective sleep 
quality over the previous month. Assessment will be 
completed in about 20 minutes. This will only be 
administered at baseline.  
Baecke’s Physical Activity Questionnaire:  Physical activity 
will be assessed using 16 questions involving three habitual 
physical activities (occupational physical activity, physical 
GENE -FORECAST SIT  
29JUL 2024 
 
29 
 exercise, and leisure activities) during the previous [ADDRESS_1040076] -SIT  
staff 
f) [ADDRESS_1040077] 24 hours using an automated dietary 
analysis software application developed by [CONTACT_759571]. The intakes for 108 nutrients 
(includin g salt) will be calculated for each participant based 
on individual diet.  
 
g) Psychophysical 
Taste Task: Sucrose 
and Salt Detection 
Thresholds  Sucrose and salt detection thresholds will be assessed using a 
two-alternative forced -choice staircase procedure was 
developed at the Monell Center for Adults. The two -
alternative forced choice is a psychophysical method 
developed to elicit responses about an individual’s experience 
regarding a stimulus. It focuses on the evaluation of a single 
attribute (e.g., sweetness or saltiness), and the stimulus is 
adjuste d based on the individual’s responses . After tasting 
both solutions within a pair, subjects will  be asked to point to 
the solution that has a non -neutral taste. A tracking grid will 
be used to record subjects’ response.19-[ADDRESS_1040078]. Paule Joseph.  
h) Psychophysical 
Taste Task: Sucrose 
and Salt Preference  Sucrose and salt preference will be assessed using a two -
series paired comparison -tracking method developed at the 
Monell Center for Adults.14-16 Subjects will be presented with 
pairs of solutions differing in sucrose concentration (3, 6, 12, 
24, and 36 g per 100 mL) and salt (0.92 –6.14% wt/vol NaCl ). 
They will be asked to taste the solutions without swallowing 
and point to which of the pair they liked better. Subsequently, 
each pair presented will be determined by [CONTACT_423]’s 
preceding preference choice.  The entire task is then repeated 
with the stimulus pairs presented in reverse order. After 
completion of the taste task, the geometric mean of the 
sucrose concentrations chosen will be determined. This 
serves as  an estimate of the participant's most preferred level  
of sucrose.22-[ADDRESS_1040079]. Paule Joseph.  
 
i) Vascular Function  These tests will be done using specialized non -invasive 
machines, such as SphygmoCor and EndoPAT, to assess 
vascular health  conducted by [CONTACT_759572].  
GENE -FORECAST SIT  
29JUL 2024 
 
30 
   
  
 
Biological specimen collection and laboratory evaluations:  
Biological specimen  
  
          Clinical Center  
Research  Lab 
Test 
Lab test  Volume  
Tube (ml)  Number of 
Tubes  Total 
Volume 
(ml) Total 
Volume 
(tablespoon )  Tube type  
CBC: CBC with 
differential count  
4 2 8 0.54 Lavender  HbA1C: A1C  
 
Homocysteine  
Fasting lipid 
panel (serum):  
3.5 2 7 0.47 green/yellow  Mineral panel  
Acute Care Panel  
 Total Protein  
ApoA1 and 
ApoB: APOAB  
Pro-BNP: BNP1  
C-reactive 
protein: CRPHS 
(high sensitivity 
CRP)  
Hepatic Panel  3.5 1 3.5 0.24 Gold  Serum hCG  
Serum Cortisol  
(CORT)  
8.[ADDRESS_1040080]  Serum 
Aldosterone   
(ALD03,ADS01, 
ADS02)  
GENE -FORECAST SIT  
29JUL [ADDRESS_1040081]  Volume 
Tube 
(ml) Number 
of 
Tubes  Total 
Volume 
(ml) Total 
Volume 
(tablespoon 
) Tube type  
 
4 1 4 0.27 Lavender/EDTA  DNA isolation 
(research, whole 
blood)  
RNA/miRNA 
isolation (whole 
blood)  2.5 2 5 0.34 PaxGene  
Plasma for research 
archiving  4 1 4 0.27 Green/ Lithium Heparin  
 
3.[ADDRESS_1040082]   
Research tube for 
specialized 
endothelial function 
markers (e.g. 
VCAM -1, VEGF)  
Research tube for 
specialized 
inflammatory 
markers (e.g. IL6, 
TNF alpha)  
Plasma Renin 
Activity (PRA, 
PRAK1)  4 1 1 0.20 Lavendar/EDTA  
Serum for research 
archiving  3.[ADDRESS_1040083]  
FACS Analysis  10 4 40 2.71 Green/ Sodium Heparin  
Non-Clinical 
Center Research  
Labs Total  27.[ADDRESS_1040084] SIT  
29JUL 2024 
 
32 
 Total per visit        
(4 visits)  47 16 87 5.88   
 
Microbiome:  
 
BODY SITE  SPECIMEN  COLLECTI ON TUBE  
 
Oral Cavity   
 
Saliva  
 
  
Saliva DNA  Collection, 
Preservation, and Isolation 
Kit  
 
 
Skin  Retroauricular Crease ( Left)  
Swab Collection and DNA 
System  Retroauricular Crease ( Right ) 
Antecubital Fossa ( Left) 
Antecubital Fossa (Right)  
 
GI Tract   
Stool   
Norgen Stool Nucleic Acid 
Collection and Preservation 
System  
 
Total volu me of blood collected per visit = 87 ml, whi ch is equiv alent to about  5.8-6 tabl espoons 
of blood.  More detailed description of all procedures can be found in the study MOP.  
 
Laboratory evaluations:  
DNA and RNA extractions will be done by [CONTACT_759573], Inc. DNA and RNA sequencing 
will be done by [CONTACT_759574] (NISC). Microbiome assay will be done 
by [CONTACT_759575].  Flow Activating Flow Cell Sorting ( FACS ) 
Analysis  will be conducted by [CONTACT_15792]’s Flow Cytometry Core in collaboration with [CONTACT_759587] 
McCoy.  
 
Adverse Events and Serious Adverse Events  
8.2.5 Definition of Adverse Event  
We will define an adverse event (AE) as any untoward medical occurrence associated with the 
use of an intervention in humans, whether considered intervention relation based on 21 CFR 
312.32(a).  
 
8.2.6 Definition of Serious Adverse Events (SAE)  
8.2.7 Classification of an Adverse Event  
We will define a SAE or suspected SAE as “serious” if, in the view of either the investigator or 
sponsor, it results in any of the following outcomes: death, a life -threatening adverse event, 
inpatient hospi[INVESTIGATOR_8686], a persistent or significant 
incapacity of substantial disruption of the ability to conduct normal life functions, or a congenital 
GENE -FORECAST SIT  
29JUL 2024 
 
33 
 anomaly/birth defect.  Important medical events that may not result in death, life threatening, or 
require hospi[INVESTIGATOR_708], based upon appropriate medical 
judgment, they may jeopardize the participant and may require medical or surgical intervention 
to prevent one of the outcomes listed in the definition.  Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not resu lt in inpatient hospi[INVESTIGATOR_48802].  
 
[IP_ADDRESS]  Severity of Event  
All Adverse Events (AEs) will be assessed by [CONTACT_759576]. For AEs not included in the 
protocol defined grading system, the following guidelines will be used to describe severity.  
Mild:  Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
 
Moderate:  Events result in a low level of inconvenience or concern with the therapeutic 
measures.  Moderate events may cause some interferences with functioning.  
 
Severe:  Events interrupt a participant’s usual daily activities and may require systemic 
drug therapy or other treatment.  Severe events are usually potentially life -threatening or 
incapacitating.  Of note, the term “severe” does not necessarily equate to “seriou s”. 
 
[IP_ADDRESS]  Relationship to Study Intervention  
All adverse events (AEs) must have their relationship to study intervention assessed by [CONTACT_978], in 
consultation with clinical study staff, who will examine and evaluate the participant based on 
temporal relationship and his clinical judgement.  The degree of certainty about causality will be 
graded using the categories below.  In a clinical trial, the study product must always be suspect.  
 
Related:  The AE is known to occur with the study intervention, when there is a reasonable 
possibility that the study intervention caused the AE, or there is a temporal relationship between 
the study intervention and event.  Reasonable possibility means that there is evidence to suggest 
a causal relationship between the study intervention and the AE.  
 
Not Related:  There is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study intervention 
and event onset, or an alternate etiology has been established.  
 
OR 
 
Definitely Related:  There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out.  The clinical event, including an abnormal laboratory test 
result, occurs in a plausible time relationship to study intervention administrat ion and cannot be 
explained by [CONTACT_9153].  The response to withdrawal of the 
study intervention should be clinically plausible.  The event must be pharmacologically or 
phenomenologically definitive, with use of a satisfactory re -challenge procedure if necessary.  
 
GENE -FORECAST SIT  
29JUL 2024 
 
34 
 Probably Related:  There is evidence to suggest a causal relationship, and the influence of 
other factors is unlikely.  The clinical event, including an abnormal laboratory test result, occurs 
within a reasonable time after administration of the study intervention, is unlike ly to be attributed 
to concurrent disease or other drugs or chemicals, and follows a clinically reasonable response on 
withdrawal (de -challenge).  Re -challenge information is not required to fulfill this definition.  
 
Potentially Related:  There is some evidence to suggest a causal relationship (e.g., the event 
occurred within a reasonable time after administration of the trial medication). However, other 
factors may have contributed to the event (e.g., the participant’s clinical condition, other 
concomitant events). Although an AE may rate only as “possibly related” soon after discovery, it 
can be flagged as requiring more information and later be upgraded to “probably related” or 
“definitely related”, as appropriate.  
 
Unlikely to be Related:  A clinical event, including an abnormal laboratory test result, 
whose temporal relationship to study intervention administration makes a causal relationship 
improbable (e.g., the event did not occur within a reasonable time after administration of the 
study intervention and in which other drugs or chemicals or underlying disease provides 
plausible explanations (e.g., the participant’s clinical condition, other concomitant treatments).  
 
Not Related:  The AE is completely independent of study intervention administration, and/or 
evidence exists that the event is definitely related to another etiology.  There must be an 
alternative, definitive etiology documented by [CONTACT_15370].  
 
[IP_ADDRESS]  Expectedness  
The Staff Clinician will be responsible for determining whether and AE is expected or 
unexpected.  An AE will be considered unexpected if the nature, severity, or frequency of the 
event is not consistent with the risk information previously described for t he study intervention.  
 
8.2.8 Time Period and Frequency for Event Assessment and Follow -Up 
The occurrence of an AE or SAE may come to the attention of clinical study staff during study 
visits and follow -up after study visit to assess reaction(s) to intervention product.  
 
All AEs including local and systemic reactions not meeting the criteria for SAEs will be capture 
on the appropriate Case Report Form (CRF).  Information to be collected includes events 
description, time of onset, Staff Clinician’s assessment of severity, relationship to study product 
and time of resolution/stabilization of the event.  All AEs occurring while  on study will be 
documented appropriately regardless of relationship.  All AEs will be followed to adequate 
resolution.  
 
Any medical condition that is present at the time that the participant is screened will be 
considered as baseline and not reported as an AE.  However, if the study participant’s condition 
deteriorates at any time during the study, it will be recorded as an  AE. 
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of 
the event at each level of severity to be performed.  AEs characterized as intermittent require 
documentation of onset and duration of each epi[INVESTIGATOR_1865].  
GENE -FORECAST SIT  
29JUL 2024 
 
35 
  
The study’s Physician Assistant will record all reportable events with start dates occurring any 
time after informed consent is obtained until 7 days (for non -serious AEs) or 30 days (for SAEs) 
after the last day of study participation.  At each study visi t, the PI [INVESTIGATOR_759515]/SAEs since the last visit.  Events will be followed for outcome information 
until resolution or stabilization.  
 
[IP_ADDRESS] Adverse Event Reporting  
The study PI [INVESTIGATOR_759516].  The PI [INVESTIGATOR_759517].  Full details of procedures, including flow chart, will be  included in the study’s Manual 
of Operating Procedures (MOP).  Potential s ide effects associated with the intervention product 
(i.e. sodium chloride) may include discomfort while swallowing, increased thirst, indigestion, 
nausea, vomiting, headaches, mild  elevations in blood pressure, mild changes in blood chemicals 
(electrolytes), lightheadedness, tiredness, mild swelling of arms/legs, and/or diarrhea , and rash. 
There are no disease related conditions related to the intervention product.  
8.2.8 Serious Adverse Event Reporting  
The study PI [INVESTIGATOR_759518], whether or not 
considered study intervention related, including those listed in the protocol and will include an 
assessment of whether there is a reasonable possibility that the  study intervention caused the 
event.  Study endpoints that are SAEs (e.g., all -cause mortality) must be reported in accordance 
with the protocol unless there is evidence suggesting a causal relationship between the study 
intervention and the event (e.g., death from anaphylaxis).   
 
All SAEs will be followed until satisfactory resolution or until the PI [INVESTIGATOR_759519].  Other supporting documentation of the event will be made 
available to the Independent Safety Monitor or Intramural Program as soon as possible upon 
request.  
 
8.2.[ADDRESS_1040085] positive at any subsequent visit or becomes pregnant in between visits, she will be 
discontinued, and this will be reported as an AE to t he NIH IRB during the time of continuing 
review.  
8.3 UNANTICIPATED PROBLEMS  
8.3.1 Definition of Unanticipated Problems (UP)  
Any incident, experience, or outcome that meets all of the following criteria shall be considered 
an UP:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures 
that are described in the protocol related documents, such as the IRB -approved research protocol 
and informed consent documents; and (b) the characteristics of the participant population being 
studied; and  
GENE -FORECAST SIT  
29JUL 2024 
 
36 
 • Related or possibly related to participation in the research (“possibly related” means there 
is a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_9156]); and  
• Suggests that the research places participants or others (which many include research 
staff, family members or other individuals not directly participating in the research) at a greater 
risk of harm (including physical, psychological, economic, or social h arm) than was previously 
known or expected.  
8.3.2 Unanticipated Problem Reporting  
The investigator will report unanticipated problems (UPs) to the NIH Institutional Review Board 
(IRB) as per Policy 801.  
8.3.[ADDRESS_1040086] a formal Statistical Analytical Plan (SAP).  
9.1 STATISTICAL HYPOTHESIS  
1) Increased dietary sodium intake will be associated with vascular dysfunction and increased 
blood pressure in the treatment group compared to the placebo group.  
2) Increased dietary sodium intake will be associated with changes in the whole blood epi[INVESTIGATOR_759520].  
3) Increased dietary sodium intake will be associated with changes in the whole blood and urine 
transcriptome as assessed by [CONTACT_16638] -seq in the treatment group compared to the placebo group.  
4) Increased dietary sodium intake will be associated with changes in the skin, oral and gut 
microbiome in the treatment group compared to the placebo group.  
5) Increased dietary sodium take will be associated with blood epi[INVESTIGATOR_307999]/transcriptome 
molecular signature [CONTACT_759586].   
 
Endpoints:  
Primary:  
Vascular function  
Microbiome  
      Secon dary:  
      Blood pressure  
      Whole blood epi[INVESTIGATOR_759521]  
9.[ADDRESS_1040087]. Continuous variables will be 
described as mean ± standard deviation (SD) if normally distribute. Variables with skewed 
distribution (i.e.  aldosterone , BNP, etc.) were logarithmically transformed prior to analyses and 
are presented as median and interquartile range (IQR).  Categorical variables will be expressed 
as numbers (percentages).  
When data are normally distributed, comparisons between the treatment (sodium intake) and 
control (placebo) groups will be made using paired Student’s t -tests, and when data are non -
GENE -FORECAST SIT  
29JUL [ADDRESS_1040088] on the averages in the two treatment peri ods. Correlations were determined with Pearson's 
correlation coefficient.  
Additionally, we will evaluate the effects of sodium intake on changes in blood pressure, 24-hr 
ambulatory blood pressure monitoring ( ABPM ), biochemical markers, vascular functions, and 
specific transcriptome and epi[INVESTIGATOR_759522] a linear mixed model, with subject as a random 
effect, thereby [CONTACT_759577], sequence, and carryover effects and to model the 
various sources of intra -individual and inter -individual variability.  All statistical tests will be 
two-sided and P values <0·05 will be reg arded as significant.  Statistical analyses will be carried 
out using SAS software (SAS Institute, Inc., Cary, NC, [LOCATION_003]).  
Sample size and statistical power:  We expect to enroll and randomize a total of  [ADDRESS_1040089] meaningful effects of sodium 
intake on the study’s primary outcomes and secondary outcomes, including changes  in vascular 
function (PWV m/s), sitting SBP and DBP (mm Hg), ABPM (mm Hg), biochemical markers 
(plasma aldosterone, pg/mL, brain natriuretic peptide (pg/mL ), as well as epi[INVESTIGATOR_307999], 
transcriptome, and microbiome under an assumption about the effe ct size, standard deviation 
outcomes, correlation of measurements within individual. We estimated that a sample size of [ADDRESS_1040090] changes in PWV between high salt 
intake and control groups of 0.6 m/s ( estimates based on Pi[INVESTIGATOR_759523]. 47), with 80% power and 
P < 0.05, assuming common SD of 0.9 m/s for high sodium intake and control groups, and 
correlation of 0.3 within subjects (Figure 2).  Accounting for  a potential of 20% dropout during 
the study, the  sample size would be 34.  
In addition, the estimated sample size will provide us with more than [ADDRESS_1040091] 
a difference of 6  mm Hg (SD=9  mm Hg) in sitting SBP between sodium intake and the placebo 
treatment at 0.05 significance level (estimates based on  Tzemos et al. 48).  Similarly, the 
proposed sample size would give more than 90% power to detect significant changes in plasma 
aldosterone (pg/ml) and brain natriuretic peptide (pg /mL) between high sodium intake and 
control at 0.[ADDRESS_1040092], vascular function difference between placebo and treatment (salt intake) will be estimated. 
Then, microbiome differential between treatment and placebo will be identified and estimate for 
each of the microbiome collection sides (skin, oral and gut). Details of the vascular function and 
microbiome analyses with respect to treatment and placebo are provided below.  
 
Vascular function (e.g. pulse wave velocity , PWV ) will be first analyzed as a continuous 
variable. Its relationship with salt intake will be investigated through multiple linear regression 
with vascular function as outcome and salt intake (a binary variable with two categories: 

GENE -FORECAST SIT  
29JUL 2024 
 
39 
 treatment and placebo) as  exposure variable . For this analysis only samples with complete data 
for vascular function and salt intake will be considered. The outcome  variable  will be log 
transformed if it departs markedly from the Gaussian distribution. The aim of this first analysis is 
to estimate the effect of salt intake on vascular function. The effect size, p -value and 95% 
confidence interval will be provided as results.  
 
The second endpoint  is microbiome ; the microbiome data of each of the all the collection  sites 
(oral, gut and  skins ) will be analyzed separately.  Prior to investigating the relationship between 
microbiome  and salt intake, the raw microbiome data requires extensive processing and quality 
control s (QC) because of challenges posed by [CONTACT_759578] 30,31 and the potential of spurious 
results if appropriate QC are not applied. The raw data will be processed in mainly 5 steps: (a) 
reads preparation (assembly of paired reads, filtering of low quality reads and identification of 
unique sequences), (b) Operational Taxonomic Units - OTU clustering (selection of unique OTU 
sequences) , (c) quality controls (identificat ion and removal of artifacts from amplicon reads, in 
OUT sequences). These tasks will be carried out using pi[INVESTIGATOR_759524] (SOPs) developed and used by [CONTACT_759579] 31,32. For 
the metagenomic microbiome data, the HUMAnN2  33 pi[INVESTIGATOR_759525] 16s 
microbiome data the DADA2  34 pi[INVESTIGATOR_759526].  
 
The output of the pi[INVESTIGATOR_759527], not continuous, and include only 
positive values 30,33,34. The counts, C ij, are the observed number of microbes for the  ith sample 
and jth feature  where the features are the OTUs or microbial taxa. The data are normalized 
because library sizes (total counts for each sample, across all features) often have a large 
magnitude difference, which can cause a bias 35. The data are right skewed with , usually, a large 
numb er of data points having the value 0.  Such data follows a Poisson distribution  and therefore 
a Poisson regression model type (e.g. negative binomial model) will be used to investigate the 
relationship between microbiome and salt intake.  For each feature, a model will be fitted with the 
feature as outcome and salt intake (a binary variable with two categories: treatment and placebo)  
as covariate. The differential count (fold change difference) between treatment and placebo will 
be estimated for each feature (OTU). To adjust for the multiple testing of several OTUs,  a false 
discovery rate penalty will be applied and only fold changes with an adjusted p -value 
(Benjamini -Hochberg multiple test correction) smaller or equal to 0.05 will be considered 
statistically significant.  
 
The analysis describe s above using a Poisson regression model assumes the features (OTUs) are 
independent but it  has been shown that microbial communities do interact in such way that 
changes in one feature affect another feature  36-38. However, the number of interactions can be 
large due to the number of features, and not easily fitted in a conventional regression model.  
Therefore, a machine learning algorithm (Random Forest or Neural Network) will be used to 
investigate the combined response of the featu res to salt intake. These algorithm s can incorporate  
multiple and complex interactions between features  without making an assumption about their 
distribution . The features will be used as predictor variables to predict salt intake (a binary 
variable with two categories: treatment and placebo) . The results will be presented as the area 
under the curve (AUC) of a receiver operating curve (ROC) that reflect how well the features can 
predict treatment and placebo.  Because these ensemble techniques do not assume the predictors 
GENE -FORECAST SIT  
29JUL 2024 
 
40 
 variable (OTUs) are independent, no multiple testing penalty is required but rather cross -
validation will be undertaken.  
 
9.4.3 Analysis of the Secondary Endpoint(s)  
The secondary endpoints will be assessed independent of the results associated with the primary 
endpoints; secondary endpoints include blood pressure, whole blood epi[INVESTIGATOR_307999], and whole blood 
and urine transcriptome.  The effect of treatment and placebo will be investigated will be 
investigated for each secondary endpoint, as detailed below.  
 
The association between blood pressure (systolic and diastolic) and salt intake will be assessed 
using  multiple linear regression with salt intake (two categories: treatment and placebo ) as the 
exposure variable  and blood pressure outcome variable . The effect size, p -value and 95% 
confidence interval of the regression model will be provided as results.  
 
The effect of salt intake on gene expression will be investigate d in a differential expression 
analysis to identify genes whose expression differs significantly between treatment and placebo. 
The gene expression data will be normalized, using the weighted trimmed mean of M -values 
(TMM) method, an optimal method for the normalization of mRNA count data 39. Genes with an 
expression less than  1 Count Per Million (CPM = count/sum [counts] x 1million) in at least 2 
samples w ill be excluded because results from genes with extremely low expression are not 
reliable. Gene express ion is generated as count data which follows a Poisson distribution ; 
therefore, a negative binomial model will be fitted using the R library edgeR  [ADDRESS_1040093] from the average  dispersion . Dispersion outlier s will not be considered for the results 
because the deviance indicate s low quality or marked expression difference  for the gene.  
Finally, g enes with a log fold change  not equal to  0 and a false discovery rate adjusted  p-value ≤ 
0.[ADDRESS_1040094] of salt intake will be investigated trough a two -sample  t–test to identify 
methylation sites with significant methylation level difference between treatment and placebo.  At 
a minimum of 5X coverage and an average  coverage of 30X, the SureSelect -MethSeq (SS-
Methseq) platform capture s between  2.6 and 2.3  million methylation sites 41. After thorough  
processing and QC of the methylation data, using the Bismark pi[INVESTIGATOR_19189] 42, samples and 
methylation sites that passed all QC filters will be considered for the analysis.  Each methylation 
site will be treated as a continuous variable and salt intake will be treated as a nominal variable 
with two categories (treatment and placebo), in the t -test. In such analysis, the methyla tion sites 
are assumed to be independent and there is, hence , a high burden of multiple testing due to the 
millions of sites being tested. Therefore,  a significance threshold  of p-value  < 9 × 10− 8 will be 
applied to control for false positive findings; this threshold was derived from empi[INVESTIGATOR_533503] 43 
based on the Illimunia EPIC array which has a lower density than the SS -Methseq platform but 
include s carefully selected sites that span the whole genome.  The estimated mean differenc e, p-
value and 95% confidence interval of the t -test will be presented as the results.  
GENE -FORECAST SIT  
29JUL [ADDRESS_1040095] been considered separately in the 
analyses described above and to understand the links between gene expression and methylation, 
an ensemble technique such as Random Forests will be used to leverage the high dimensionality 
of the data (number of featu res >> number of observations) 44,[ADDRESS_1040096] combination 
of predictors of salt intake in the  transcriptome and epi[INVESTIGATOR_759528]. Subsequently, the OTUs 
identified in the microbiome data will be integrated to find out if microbiome information 
improves the prediction accuracy of the omics data 46. This will provide further insights into the 
interplay between the three domains ( microbiome, transcriptome and epi[INVESTIGATOR_307999]).  
 
 
9.4.[ADDRESS_1040097] 
will be used to assess continuous variables.  
9.4.6 Planned Interim Analyses  
Not applicable  
 
9.4.7 Sub-Group Analyses  
Primary and secondary endpoints will be compared based on age and sex differences stratified by 
[CONTACT_759580]. ). 
 
9.4.8 Tabulation of individual Participant Data  
Individual participant data will not be presented by [CONTACT_7206].   
9.4.9 Exploratory Analyses  
Exploratory analyses will not be conducted.  
10 REGULATORY AND  OPERATIONAL CONSIDERATIONS  
10.1 INFORMED CONSENT PROCESS  
 
10.1.1  Consent /Assent  Procedures and Documentation  
Consent will be obtained at the NIH Clinical Center during baseline visit. The GENE -
FORECAST -SIT staff is experienced  in administer ing consent and will escort potential 
participant to a private area of the Clinical Center to discuss the consent form.  
 
The GENE -FORECAST -SIT staff will provide the individual a copy of the consent forms, read 
all sections of the consent form and solicit for any questions.  The consent process will take 
between [ADDRESS_1040098] SIT  
29JUL 2024 
 
42 
 10.1.2  Considerations for Consent of NIH staff, or family members of study team members  
Consent from staff members will be obtained by [CONTACT_165111]’s 
team whenever possible.  Otherwise, the consent procedure will be independently monitored by 
[CONTACT_759581].  
10.1.3  Participation of Subjects who are/become Decisionally Impaired  
Adults unable to provide consent are excluded from enrolling in the protocol. However, it is 
possible that subjects enrolled in the protocol may permanently lose the capacity to consent for 
themselves during the course o f this study.   In the event this occurs, the subjects will  be 
withdrawn from the study . .  
 
10.[ADDRESS_1040099] (e.g., nausea, dizziness, rash).  The possibility of a 
temporary suspension of the study is highly unlikely.  
10.[ADDRESS_1040100] party without pri or written approval of study participant.  
 
All research activities will be conducted in as private a setting as possible.  
 
Representatives of the NIH IRB and/or regulatory agencies may inspect all documents and 
records required to be maintained by [CONTACT_978], including but not limited to, medical records (office, 
clinic) and pharmacy records for the participants in this study.  Th e NIH Clinical Center will 
permit access to such records.  
 
The study participant’s contact [CONTACT_759582].  At the end of the study, all records will continue to be kept in a secure location for as long 
a period as dictated by [CONTACT_3488].  
 
Study participant research data, which is for purposes of statistical analysis and scientific 
reporting, will be transmitted to and stored on dedicated and secured NIH servers and the NIH 
electronic Clinical Trial Database (CTDB).  This will not include th e participant’s contact [INVESTIGATOR_1660], 
identified by a unique study identification number.  
  
The study data entry and study management systems used by [CONTACT_759583].  At the end of the study, all study databases will be identified and 
archived on PI’s dedicated NIH server.  
 
To further protect the privacy of study participants, a Certificate of Confidentiality has been 
issued by [CONTACT_4289].  This certificate protects identifiable research information from forced disclosure.  
It allows the investigator and others who have access to re search records to refuse to disclose 
GENE -FORECAST SIT  
29JUL [ADDRESS_1040101] an Independent Safety Monitor (ISM) responsible for safety oversight.  The ISM 
will be composed of individuals with appropriate expertise (e.g., physician, nurse , 
epi[INVESTIGATOR_47561] ), will be independent from the study and free of conflict of interest.  The ISM 
will meet at least semiannually to assess safety and efficacy data on each arm of the study.  The 
ISM will provide input to the study PI [INVESTIGATOR_6012].  
10.[ADDRESS_1040102] of the trial is in compliance with International C onference on Harmonisation Good 
Clinical Practice (ICH GCP), and with applicable regulatory requirements.  
10.[ADDRESS_1040103], data and 
biological specimen collection, documentation and completion.  An individualized quality 
management plan will be developed to describe quality management.  
 
Quality control (QC) procedures will be implemented beginning with the data entry system and 
data QC checks that will be run on the database will be generated.  Any missing data or data 
anomalies will be communicated to the PI [INVESTIGATOR_759529] f for 
clarification/resolution.  
Following written (Manual of Operating Procedures (MOP), the database manager will verify 
that the study is conducted and data are generated and biological specimens are collected, 
documented (recorded), and reported in compliance with the protocol, ICH GC P, and applicable 
regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices 
(GMP).  
 
The study will provide direct access to all source data/documents, and reports for the purpose of 
monitoring and auditing and inspection by [CONTACT_3482].  
 
10.[ADDRESS_1040104] KEEPI[INVESTIGATOR_1645]  
10.8.1  Data Collection  and Management Responsibilities  
Data collection will be the responsibility of the clinical staff (i.e., Research Nurse and Physician 
Assistant) under the supervision of the PI.  The PI [INVESTIGATOR_759530], completeness, legibility, and timeliness of the da ta reported.  
 
All source documents will be completed in a neat, legible manner and recorded in electronic 
CTDB to ensure accurate interpretation of data.  
 
GENE -FORECAST SIT  
29JUL 2024 
 
44 
 Hardcopi[INVESTIGATOR_759531].  Data recorded in the electronic case 
report form (eCRF) derived from source documents will be consisten t with the data recorded on 
the source documents.  
 
All study related data (including AEs, concomitant medications, and expected adverse reaction 
data) and clinical laboratory data will be entered into the CTDB on the PIs server.  The CTDB 
will be password protected and internal quality checks conducted by [CONTACT_253977], 
such as automatic range checks, to identify data that appear inconsistent, incomplete, or 
inaccurate.  Data will be entered directly from the source documents.  
10.8.[ADDRESS_1040105] as per Policy 801.  The PI [INVESTIGATOR_759532].  
10.9.1  NIH Definition of Protocol Deviation  
A protocol deviation will be any change, divergence, or departure from the IRB approved 
research protocol and defined as:  
• Major deviations: Deviations from the IRB approved protocol that have, or may have 
the potential to, negatively impact the rights, welfare or safety of the subject, or to 
substantially negatively impact the scientific integrity or validity of the study.  
• Minor deviations:  Deviations that do not have the potential to negatively impact the 
rights, safety or welfare of subjects or others, or the scientific integrity or validity of the 
study.  
 
10.10  PUBLICATION AND DATA SHARING POLICY  
10.10.1 Human Data Sharing Plan  
This study will be conducted in accordance with the following publication and data sharing 
policies and regulations:  
NIH Public Access Policy, which ensures that the public has access to the published results of 
NIH funded research.  This requires scientists to submit final peer -reviewed journal manuscripts 
that arise from NIH funds to the digital archive PubMed Central upon acceptance for 
publication.  
 
This study will comply with the NIH Data Sharing Policy on the Dissemination of NIH -Funded 
Clinical Trial Information and the Clinical Trials Registration and Results Information 
Submission rule.  As such, this trial will be registered at the ClinicalTrial s.gov, and results from 
this trial will be submitted to ClinicalTrials.gov.  In addition, every attempt will be made to 
publish results in peer reviewed journals.   
10.10.[ADDRESS_1040106]:SIT  Genomics, Environmental Factors and Social Determinants of 
Cardiovascular Disease In African Americans: Sodium Intervention 
Trial  
GLP  Good Laboratory Practices  
GMP  Good Manufacturing Practices  
GWAS  Genome -Wide Association Studies  
HIPAA  Health Insurance Portability and Accountability Act  
ICH International Conference on Harmonisation  
GENE -FORECAST SIT  
29JUL [ADDRESS_1040107]  National Clinical Trial  
NIH  National Institutes of Health  
NIH IC  NIH Institute or Center  
NIH IDOU  NIH Investigational Drug & Research Section Outsourcing Unit  
NHGRI  National Human Genome Research Institute  
NHLBI  National Heart, Lung, and Blood Institute  
OHRP  Office for Human Research Protections  
PI [INVESTIGATOR_759533] -oxidase  
UP Unanticipated Problem  
 
[ADDRESS_1040108] ( GENom ics, Environme ntal F actORs and the Soci al DEterminants of 
Cardiov ascular Dise ase in A frican Americans  Study) was established to explore the intricate 
relationship between the unique genomic variations characteristic of African -Americans (AA) and 
the broader array of social determinants and environmental factors, collectively known as the 
'exposome', that impact  the development of cardiovascular disease (CVD) in this population.  
The Sodium Intervention Trial  (SIT) is a clinical trial protocol (000070) aimed at investigating the 
impact of dietary salt on the cardiovascular system, leveraging the existing pool of participants of 
the GENE -FORECAST protocol (18 -HG-0048). Initially embedded within GENE -FORECAST, 
SIT sought to enroll participants who had previously consented to be re -contact[INVESTIGATOR_530]. However, as 
guidelines prohibited the inclusion of a sub -study within an ongoing natural history protocol, SIT 
was separated from GENE -FORECAST a fter recruiting an initial cohort of [ADDRESS_1040109] protocol to the SIT protocol.  
 
 
 
 
13 REFERENCES  
1. Estruch, R. et al. Primary prevention of cardiovascular disease with a Mediterranean diet. 
N Engl J Med 368, 1279 -90 (2013).  
2. Sacks, F.M. et al. Effects on blood pressure of reduced dietary sodium and the Dietary 
Approaches to Stop Hypertension (DASH) diet. DASH -Sodium Collaborative Research Group. 
N Engl J Med 344, 3 -10 (2001).  
3. Farquhar, W.B., Edwards, D.G., Jurkovitz, C.T. & Weintraub, W.S. Dietary sodium and 
health: more than just blood pressure. J Am Coll Cardiol 65, 1042 -50 (2015).  
4. Schmidlin, O., Sebastian, A.F. & Morris, R.C., Jr. What initiates the pressor effect of salt 
in salt -sensitive humans? Observations in normotensive blacks. Hypertension 49, 1032 -9 (2007).  
5. Rayner, B.L. & Spence, J.D. Hypertension in blacks: insights from Africa. J Hypertens 
35, 234 -239 (2017).  
6. Mell, B. et al. Evidence for a link between gut microbiota and hypertension in the Dahl 
rat. Physiol Genomics 47, 187 -97 (2015).  
7. Binger, K.J. et al. High salt reduces the activation of IL -4- and IL -13-stimulated 
macrophages. J Clin Invest 125, 4223 -38 (2015).  
8. Brian, MS, et al. Dietary sodium and nocturnal blood pressure dippi[INVESTIGATOR_759534]. J Hum Hypertens 31, 145 -150 (2017).  
9. Cava, A et al. The role of cyclo -oxygenase -1 in high salt diet -induced microvascular 
dysfunction in human. J Physiol 593, 5313 -24 (2015).  
10. Cho, H.Y., Park, H.C. and Ha, S. K. Salt sensitivity and hypertension: a paradigm shift 
from kidney malfunction to vascular endothelial dysfunction. Electrolyte Blood Press 13, 7 -13 
(2015).  
11. Liu, Y. et al. CD8+ T cells stimulate Na -Cl co -transporter NCC in distal convoluted 
tubules leading to salt -sensitive hypertension. Nat Commun 8, [ZIP_CODE] (2017).  
12. Tang, W.H. & Hazen, S.L. The Gut Microbiome and Its Role in Cardiovascular Diseases. 
Circulation 135, 1008 -1010 (2017).  
13. Tang, W.H. et al. Intestinal microbial metabolism of phosphatidylcholine and 
cardiovascular risk. N Engl J Med 368, 1575 -84 (2013).  
14. Cowart, B. and G. Beauchamp, Early development of taste perception. Psychological 
basis of sensory evaluation, 1990: p. 1 -17. 
15. Mennella, J.A., et al., Evaluation of the Monell forced -choice, paired -comparison 
tracking procedure for determining sweet taste preferences across the lifespan. Chem Senses, 
2011. 36(4): p. 345 -55. 
16. Pepi[INVESTIGATOR_8614], M.Y. and J.A. Mennella, Effects of cigarette smoking and family history of 
alcoholism on sweet taste perception and food cravings in women. Alcohol Clin Exp Res, 2007. 
31(11): p. 1891 -9. 
17. Bartoshuk, L.M., The psychophysics of taste. Am J Clin Nutr, 1978. 31(6): p. 1068 -77. 
18. Jogan, M. and A.A. Stocker, A new two -alternative forced choice method for the 
unbiased characterization of perceptual bias and discriminability. J Vis, 2014. 14(3): p. 20.  
GENE -FORECAST SIT  
29JUL 2024 
 
48 
 19. Bobowski, N.K. and J.A. Mennella, Disruption in the Relationship between Blood 
Pressure and Salty Taste Thresholds among Overweight and Obese Children. J Acad Nutr Diet, 
2015. 115(8): p. 1272 -82. 
20. Joseph, P.V., D.R. Reed, and J.A. Mennella, Individual Differences Among Children in 
Sucrose Detection Thresholds: Relationship With Age, Gender, and Bitter Taste Genotype. Nurs 
Res, 2016. 65(1): p. [ADDRESS_1040110] lower monosodium glutamate taste sensitivity 
and prefer higher concentrations than do normal -weight women. Obesity (Silver Spring), 2010. 
18(5): p. 959 -65. 
22. Mennella, J.A., et al., Preferences for salty and sweet tastes are elevated and related to 
each other during childhood. PLoS One, 2014. 9(3): p. e92201.  
23. Mennella, J.A. and N.K. Bobowski, Psychophysical Tracking Method to Measure Taste 
Preferences in Children and Adults. J Vis Exp, 2016(113).  
24. Baecke JAH, Burema J, Frigters JER, A short questionnaire for the measurement of 
habitual physical activity in epi[INVESTIGATOR_9037]. Am J Clin Nutr. 1982; 36:936 -942. 
25. Buysse DJ, Reynolds C F, Monk TH, Berman SR, Kup fer DJ.  The  Pi[INVESTIGATOR_759535]: A n ew instrum ent for  psychiatric practice and research. Psychiatry Research. 19 89; 
28(2):193-213. 
26. Krishnan K, Chen T, Paster BJ. A practical guide to the oral microbiome and its relation to 
health and disease. Oral Dis. 2017 Apr;23(3):276 -286 
27. Sánchez -García S, Heredia -Ponce E, Juárez -Cedillo T, Gallegos -Carrillo K, Espi[INVESTIGATOR_342370] -
Bermúdez C, de la Fuente -Hernández J, García -Peña C. Psychometric properties of the 
General Oral Health Assessment Index (GOHAI) and dental status of an elderly Mexican 
popul ation. J Public Health Dent. 2010 Fall;70(4):300 -7. 
28. Grice, E., Segre, J. The skin microbiome.  Nat Rev Microbiol  9, 244–253 (2011).  
29. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC; NISC Comparative 
Sequencing Program, Bouffard GG, Blakesley RW, Murray PR, Green ED, Turner ML, 
Segre JA. Topographical and temporal diversity of the human skin microbiome. Science. 
2009 May 29;324 (5931):1190 -2. 
30. Bolyen E, Knight R, and Caporaso JG. et al. 2019. Reproducible, interactive, scalable and 
extensible microbiome data science using QIIME 2.  Nature Biotechnology  37: 852 –857. 
31. A framework for human microbiome research. Human Microbiome Project Consortium, 
Nature, 486 (2012), pp. [ADDRESS_1040111] Consortium, Nature, 486 (2012), pp. 207 –[ADDRESS_1040112] G, Thompson LR, Schirmer M, Weingart G, 
Schwarzberg Lipson K, Knight R, Caporaso JG, Segata N, Huttenhower C. Species -level 
functional profiling of metagenomes and metatranscriptomes. Nat Methods 15: 962 -968 
(2018)  
34. Callahan, B., McMurdie, P., Rosen, M. et al. DADA2: High -resolution sample inference 
from Illumina amplicon data. Nat Methods 13, 581 –583 (2016).  
35. Weiss, S., Xu, Z.Z., Peddada, S.  et al.  Normalization and microbial differential abundance 
strategies depend upon data characteristics.  Microbiome  5, 27 (2017).  
36. Pacheco, A.R., Moel, M. & Segr è, D. Costless metabolic secretions as drivers of interspecies 
interactions in microbial ecosystems.  Nat Commun  10, 103 (2019).  
GENE -FORECAST SIT  
29JUL [ADDRESS_1040113] CB, He ath AC, Gordon JI. Gut microbiota from twins discordant for obesity 
modulate metabolism in mice. Science. 2013 Sep 6;341(6150):1241214.  
38. Weiss S, Van Treuren W, Lozupone C, et al. Correlation detection strategies in microbial 
data sets vary widely in sensitivity and precision.  ISME J . 2016;10(7):1669 -1681.  
39. Robinson MD, Oshlack A. A scaling normalization method for differential expression 
analysis of RNA -seq data. Genome biology. 2010;11(3):R25.  
40. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential 
expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139 –40. 
41. Walker DL, Bhagwate AV, Baheti S, Smalley RL, Hilker CA, Sun Z, Cunningham JM. DNA 
methylation profiling: comparison of genome -wide sequencing methods and the Infinium 
Human Methylation 450 Bead Chip. Epi[INVESTIGATOR_241188]. 2015;7(8):1287 -302. 
42. Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite -Seq 
applications. Bioinformatics. 2011 Jun 1;27(11):1571 -2. doi: 10.1093/bioinformatics/btr167. 
Epub 2011 Apr 14.  
43. Mansell, G., Gorrie -Stone, T.J., Bao, Y.  et al.  Guidance for DNA methylation studies: 
statistical insights from the Illumina EPIC array.  BMC Genomics  20, 366 (2019).  
44. Breiman, L. Classification and regression trees , x, 358 p. (Wadsworth International Group, 
Belmont, Calif., 1984).  
45. Boulesteix, A.L., Janitza, S., Hapfelmeier , A., Van Steen, K. & Strobl, C. Letter to the 
Editor: On the term 'interaction' and related phrases in the literature on Random Forests. Brief 
Bioinform  16, 338 -45 (2015)  
46. Shankar J. Insights into study design and statistical analyses in translational microbiome 
studies.  Ann Transl Med . 2017;5(12):249. doi:10.[ZIP_CODE]/atm.2017.01.13  
47. Pi[INVESTIGATOR_274650] E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of 
dietary sodium reduction on blood pressure in subjects with resistant hypertension: results 
from a randomized trial. Hypertension .  
48. Tzemos N, Lim PO, Wong S, Struthers AD, MacDonald TM. Adverse cardiovascular effects 
of acute salt loading in young normotensive individuals. Hypertension. 2008 Jun;51(6):1525 -
30.  